ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.03 per share a year ago. These figures ...

Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the ...

Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to ...

The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is ...

Genmab has received approval from Japan's Ministry of Health, Labour and Welfare for its Tivdak to treat cervical cancer.

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

By acquiring Araris' innovative ADC drug discovery technology platform along with Cysteinomix, Taiho Pharmaceutical will further expand its ongoing development portfolio in the field of oncology.

Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended ...

Ladenburg, Germany, 26 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting ...